GeoVax Labs, Inc. (GOVX): Nasdaq/NYSE listing notice — GeoVax Labs receives Nasdaq bid price deficiency notice; 180 days to regain compliance

GeoVax Labs, Inc.

GeoVax (GOVX) received Nasdaq deficiency letter on Dec 9, 2022 for closing bid price below $1.00 for 30 consecutive days.
Initial compliance period expires June 7, 2023; stock must close at $1.00+ for 10 consecutive days to regain compliance.
If not compliant by June 7, 2023, company may be eligible for additional 180-day period; delisting possible if not cured.
No immediate effect on Nasdaq listing; common stock continues trading under 'GOVX'.
Company says it will monitor bid price and consider available options, including possible reverse stock split.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

GeoVax Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 9, 2022, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until June 7, 2023 (the “Compliance Date”), to

View on SEC.gov

Browse all listing & compliance notices →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-028813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.